Beisheng Bio
倍生生物
Beisheng Bio (倍生生物) is a synthetic biology company focused on species design and application, founded and led by CEO Chen Yu (陈钰) . The company's stated long-term goal is to build a complete biotechnology ecosystem based on its ArchiCel architecture, which it describes as aspiring to become the "Windows + x86 architecture" of the biotech sector .
In mid-2022, the company completed two funding rounds within six months. Its angel round was led by Linear Capital with co-investment from Oasis Capital and Sequoia China, following a seed round led by Sequoia China Seed Fund with participation from MiraclePlus and Sky9 Capital . Linear Capital highlighted the company in its 2022 year-in-review as part of its life science portfolio .
elsewhere's corpus does not cover more recent developments beyond 2022 for this company.
AI-generated — may contain errors, please verify.